We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.1%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.9B
AUM Growth
+$737M
Cap. Flow
-$219M
Cap. Flow %
-1.29%
Top 10 Hldgs %
56.42%
Holding
122
New
26
Increased
36
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$353M
2
EQIX icon
Equinix
EQIX
+$266M
3
BKNG icon
Booking.com
BKNG
+$252M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$203M
5
AABA
Altaba Inc
AABA
+$162M

Top Sells

Rank Stock Value
1
KDP icon
Keurig Dr Pepper
KDP
+$596M
2
XL
XL Group Ltd.
XL
+$407M
3
LOGM
LogMein, Inc.
LOGM
+$214M
4
GILD icon
Gilead Sciences
GILD
+$207M
5
IQV icon
IQVIA
IQV
+$126M

Sector Composition

Rank Sector Weight
1 Healthcare 24.46%
2 Technology 17.58%
3 Communication Services 13.12%
4 Financials 12.19%
5 Industrials 9.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBTYK icon
26
Liberty Global Class C
LBTYK
$3.55B
$197M 1.16%
6,991,640
+1,468,984
+27% +$39.7M
LBTYA icon
27
Liberty Global Class A
LBTYA
$3.63B
$192M 1.13%
6,629,602
+1,302,109
+24% +$36.3M
VRSK icon
28
Verisk Analytics
VRSK
$24.4B
$172M 1.01%
1,424,553
-397,149
-22% -$46.2M
BPYU
29
DELISTED
Brookfield Property REIT Inc. Class A Common Stock
BPYU
$169M 1%
+8,054,215
New +$162M
NXPI icon
30
NXP Semiconductors
NXPI
$56.9B
$141M 0.83%
1,650,000
-1,023,802
-38% -$98.2M
AZN icon
31
AstraZeneca
AZN
$257B
$135M 0.8%
1,710,000
-215,000
-11% -$16.3M
EFX icon
32
Equifax
EFX
$22.6B
$107M 0.63%
815,817
-23,142
-3% -$3.01M
XLRN
33
DELISTED
Acceleron Pharma
XLRN
$105M 0.62%
1,840,732
+439,732
+31% +$21.6M
ASND icon
34
Ascendis Pharma A/S
ASND
$16.6B
$103M 0.61%
1,457,297
– –
MYOK
35
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$99.8M 0.59%
1,531,278
+50,000
+3% +$2.94M
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$89.1M 0.53%
1,795,500
+100,000
+6% +$5.09M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
$88.3M 0.52%
625,000
– –
KYNB
38
Kyntra Bio
KYNB
$30.4M
$84.7M 0.5%
55,800
-12,900
-19% -$19.9M
SINA
39
DELISTED
Sina Corp
SINA
$78.1M 0.46%
1,124,224
+489,224
+77% +$36.6M
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$77.9M 0.46%
5,125,000
+475,000
+10% +$7.28M
AVA icon
41
Avista
AVA
$3.15B
$74.3M 0.44%
1,470,000
+358,277
+32% +$18.3M
ENTA icon
42
Enanta Pharmaceuticals
ENTA
$392M
$74.1M 0.44%
867,500
-207,500
-19% -$20.8M
NVCR icon
43
NovoCure
NVCR
$1.99B
$70.7M 0.42%
1,350,000
-240,000
-15% -$9.55M
TFCFA
44
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
$66.5M 0.39%
1,435,000
+200,000
+16% +$9.16M
BABA icon
45
Alibaba
BABA
$286B
$61.5M 0.36%
+373,000
New +$66M
CA
46
DELISTED
CA, Inc.
CA
$61M 0.36%
+1,382,361
New +$59.6M
RETA
47
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$55.1M 0.33%
+673,500
New +$47.5M
AMRN
48
Amarin Corp
AMRN
$298M
$53.9M 0.32%
165,635
-58,615
-26% -$4.43M
IOVA icon
49
Iovance Biotherapeutics
IOVA
$3.76B
$53.2M 0.31%
4,725,000
+300,000
+7% +$4.26M
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
$52.1M 0.31%
1,370,000
+185,000
+16% +$8.19M
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2018 Portfolio in Review

As of Q3 2018, Thomas Steyer held 122 positions worth $16.9B, up 4.6% from $16.2B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Thomas Steyer's Q3 2018 filing shows 26 new, 36 increased, 29 reduced and 20 closed positions. Its largest new stake was Equinix: 608,600 shares worth $263M. The largest sale was Keurig Dr Pepper, an estimated $596M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 21% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q3 2018 buy was Equinix: 608,600 shares worth $263M.
  • Thomas Steyer added most to Express Scripts Holding Company in Q3 2018, an estimated $353M increase.
  • Thomas Steyer's biggest Q3 2018 reduction was IQVIA, cutting an estimated $126M.
  • Thomas Steyer fully exited Keurig Dr Pepper in Q3 2018, selling an estimated $596M.
  • Thomas Steyer's ten largest holdings make up 56% of its $16.9B portfolio in Q3 2018.
  • Thomas Steyer opened 26 new positions and closed 20 in Q3 2018.
  • Thomas Steyer's portfolio value rose 4.6% quarter-over-quarter to $16.9B.

Based on Farallon Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.